Cargando…
Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvironment promotes tumor cell survival. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is one of the first-in-class molecules for the treatment of B-CLL patients; however, the emerging mechanisms...
Autores principales: | Rimondi, Erika, Melloni, Elisabetta, Romani, Arianna, Tisato, Veronica, Casciano, Fabio, Rigolin, Gian Matteo, Milani, Daniela, Celeghini, Claudio, Zauli, Giorgio, Secchiero, Paola, Voltan, Rebecca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293193/ https://www.ncbi.nlm.nih.gov/pubmed/34287267 http://dx.doi.org/10.3390/curroncol28040223 |
Ejemplares similares
-
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016) -
The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017) -
Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1
por: Voltan, Rebecca, et al.
Publicado: (2016) -
TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
por: Bernardi, Stella, et al.
Publicado: (2019) -
Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
por: Agnoletto, Chiara, et al.
Publicado: (2014)